TY  - JOUR
AU  - Drosten, Matthias
AU  - Barbacid, Mariano
PY  - 2022
DO  - 10.1002/1878-0261.13168
UR  - http://hdl.handle.net/20.500.12105/14702
AB  - For decades, KRAS mutant lung adenocarcinomas (LUAD) have been refractory to therapeutic strategies based on personalized medicine owing to the complexity of designing inhibitors to selectively target KRAS and downstream targets with acceptable...
LA  - eng
PB  - Wiley
KW  - genetically engineered mouse tumor models
KW  - KRAS(G12C) inhibitors
KW  - lung adenocarcinoma
KW  - RAF1
KW  - RAS signaling
KW  - tumor resistance
KW  - Adenocarcinoma of Lung
KW  - Lung Neoplasms
KW  - Humans
KW  - Mutation
KW  - Oncogenes
KW  - Protein Kinase Inhibitors
KW  - Proto-Oncogene Proteins p21(ras)
TI  - Targeting KRAS mutant lung cancer: light at the end of the tunnel.
TY  - journal article
ER  -